Skip to content
DataLookout
Menu

ALB-SARDSNCT07857928

Effect of Albumin Therapy in Mechanically Ventilated Patients With Sepsis-Associated ARDS

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Notable Start date pushed from Oct 10, 2026 to Nov 20, 2026
  2. Minor Secondary endpoints: details revised at 2 of 3 entries
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Ventilator-Free Days at Day 28 (VFD-28)
Timeframe: Up to 28 days from Time Zero (T0)
Cumulative Incidence of Successful Liberation from Ventilation
Timeframe: Up to 28 days from Time Zero (T0)

Secondary (3)

Cumulative Fluid Balance
Change in Oxygenation Index (PaO2/FiO2 Ratio)
28-Day All-Cause Mortality

Arms and interventions

Prospective Observational Cohort

Patients enrolled prospectively receiving current usual clinical care, which includes a targeted human albumin treatment strategy (aiming to maintain serum albumin ≥ 30 g/L) combined with protocolized fluid de-resuscitation. Treatment decisions remain entirely under the discretion of the treating clinical team.

Historical Control Cohort

Patients identified retrospectively from electronic medical records who received usual clinical care (primarily crystalloid-based fluid management without a targeted albumin protocol) prior to the routine implementation of the targeted albumin strategy.

Sites

1 site in 1 country

  • The Second Affiliated Hospital of Hainan Medical UniversityHaikou, Hainan, China